Astellas Pharma (4503) AI Stock Analysis

• Market Cap: ¥3.57T
• Dividend Yield: 4.61%
• Average Volume (3M): 8.79M
• Price to Earnings (P/E): 28.4
• Beta (1Y): 0.48
• Revenue Growth: 13.24%
• EPS Growth: 127.88%
• Country: JP
• Employees: 14,754
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 44.22
• Shares Outstanding: 1,809,663,100
• 10 Day Avg. Volume: 9,445,439
• 30 Day Avg. Volume: 8,788,163
• PEG Ratio: 0.26
• Price to Book (P/B): 1.71
• Price to Sales (P/S): 1.35
• P/FCF Ratio: 15.73
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥1,754.50
• Price Target Upside: -10.69% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 2
• EPS Forecast (FY): 92.94
• Revenue Forecast (FY): ¥2.02T

• Rating: 73 Outperform
• Price Target: ¥1,996.00 ▲(1.60% Upside)

Astellas Pharma's strong financial performance is the most significant factor, demonstrating consistent revenue growth and robust cash flow. Technical analysis suggests caution due to overbought conditions, while the valuation indicates a potentially high price relative to earnings. The lack of earnings call and corporate events data means these factors do not influence the score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates the company's ability to expand its market reach and enhance product adoption, supporting long-term business sustainability.

Cash Flow Generation

Strong cash flow generation enhances financial flexibility, allowing for reinvestment in R&D and strategic initiatives, which is crucial for sustaining competitive advantage.

Profitability

Improved profitability reflects effective cost management and operational efficiency, which can lead to better shareholder returns and reinvestment capabilities.

Negative Factors

Debt Levels

While moderate, the existing leverage could limit financial flexibility if not managed carefully, potentially impacting future investment and growth opportunities.

Equity Utilization

Although improving, the return on equity is relatively low, suggesting that the company may not be fully optimizing its equity base for generating shareholder value.

Operational Efficiency

A low operating cash flow to net income ratio may indicate inefficiencies in converting earnings into cash, which could affect liquidity and operational agility.

Astellas Pharma Business Overview & Revenue Model

Company Description

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Astellas Pharma generates revenue primarily through the sale of prescription medications and biologics. The company has a diverse portfolio of products that contribute to its earnings, with key revenue streams coming from high-demand therapies in oncology and urology. Astellas also engages in research and development collaborations and licensing agreements with other pharmaceutical companies, which can provide additional income through upfront payments, milestone payments, and royalties on sales of partnered products. Moreover, the company invests in strategic partnerships to enhance its pipeline, further solidifying its revenue base. Astellas' commitment to innovation, driven by significant investments in R&D, allows it to capitalize on market opportunities and address unmet medical needs, thereby sustaining its profitability.

Astellas Pharma Financial Statement Overview

Summary

Astellas Pharma exhibits strong financial health with consistent revenue growth, improving profitability, and robust cash flow generation. The balance sheet reflects moderate leverage and strong equity, supporting long-term stability.

Income Statement

Astellas Pharma demonstrates strong revenue growth with a TTM increase of 1.71% and consistent gross profit margins above 74%. The net profit margin has improved to 4.19% in the TTM, indicating enhanced profitability. However, the EBIT margin shows a significant increase from previous periods, suggesting improved operational efficiency.

Balance Sheet

The company's debt-to-equity ratio remains stable at 0.60, reflecting moderate leverage. Return on equity has improved to 5.42% in the TTM, indicating better utilization of equity. The equity ratio is healthy, suggesting a strong equity base relative to total assets.

Cash Flow

Astellas Pharma's free cash flow growth is robust at 26.85% in the TTM, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 0.22, showing efficient conversion of income to cash. The free cash flow to net income ratio is high at 0.85, reflecting strong cash flow relative to earnings.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.94T	1.91T	1.60T	1.52T	1.30T	1.25T
Gross Profit	1.53T	1.43T	1.31T	1.23T	1.04T	1.00T
EBITDA	483.77B	248.30B	195.34B	240.46B	241.03B	219.83B
Net Income	81.57B	50.75B	17.05B	98.71B	124.09B	120.59B
Balance Sheet
Total Assets	3.34T	3.34T	3.57T	2.46T	2.33T	2.27T
Cash, Cash Equivalents and Short-Term Investments	215.40B	188.37B	335.69B	376.84B	315.99B	326.13B
Total Debt	889.49B	831.43B	1.01T	200.01B	212.74B	278.26B
Total Liabilities	1.85T	1.83T	1.97T	948.56B	872.09B	887.51B
Stockholders Equity	1.48T	1.51T	1.60T	1.51T	1.46T	1.39T
Cash Flow
Free Cash Flow	205.19B	164.61B	89.98B	239.23B	181.00B	229.40B
Operating Cash Flow	241.00B	201.61B	172.47B	327.77B	257.44B	306.84B
Investing Cash Flow	-73.29B	-89.42B	-845.80B	-84.50B	-62.41B	-81.89B
Financing Cash Flow	-260.49B	-261.37B	614.06B	-195.62B	-216.30B	-229.48B

Astellas Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1964.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4503, the sentiment is Positive. The current price of 1964.5 is above the 20-day moving average (MA) of 1821.87, above the 50-day MA of 1703.22, and above the 200-day MA of 1491.28, indicating a bullish trend. The MACD of 88.02 indicates Negative momentum. The RSI at 77.74 is Negative, neither overbought nor oversold. The STOCH value of 88.03 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4503.

Astellas Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4519	80 Outperform	$13.76T	34.67	20.99%	1.14%	6.25%	2.62%
4507	76 Outperform	¥2.43T	13.74	12.22%	2.54%	4.48%	11.08%
4523	74 Outperform	$1.28T	25.44	5.75%	3.53%	6.79%	22.14%
4503	73 Outperform	¥3.57T	28.44	7.97%	4.61%	13.24%	127.88%
4568	70 Outperform	$6.28T	22.46	16.66%	1.64%	12.56%	14.58%
4528	70 Outperform	$895.85B	18.48	6.03%	4.38%	4.00%	-48.73%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Astellas Pharma Corporate Events

Astellas Pharma Revises FY2025 Financial Forecasts Upward

Astellas Pharma has revised its financial forecasts for FY2025, projecting higher revenues and profits due to the strong performance of its strategic brands, including VYLOY™ for gastric cancer, PADCEV™ for urothelial cancer, and XTANDI™ for prostate cancer. The company’s cost management initiative, Sustainable Margin Transformation, is also expected to positively impact its financial performance, highlighting Astellas’ robust market positioning and strategic growth in the life sciences sector.

The most recent analyst rating on (JP:4503) stock is a Buy with a Yen1805.00 price target. To see the full list of analyst forecasts on Astellas Pharma stock, see the JP:4503 Stock Forecast page.

Astellas Pharma’s GLEAM Trial Falls Short of Primary Endpoint in Pancreatic Cancer Study

Astellas Pharma announced that its Phase 2 GLEAM trial, which investigated the combination of zolbetuximab with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer, did not meet its primary endpoint of overall survival. Despite this setback, Astellas remains committed to advancing its research in pancreatic cancer, recognizing the significant challenges associated with this aggressive disease. The company plans to further evaluate the trial data and continue its efforts to develop innovative treatments, with the financial impact of the trial’s outcome expected to be minor.

The most recent analyst rating on (JP:4503) stock is a Hold with a Yen1600.00 price target. To see the full list of analyst forecasts on Astellas Pharma stock, see the JP:4503 Stock Forecast page.

Astellas Pharma’s IZERVAY Gains Conditional Approval in Japan for Geographic Atrophy

Astellas Pharma has received conditional approval from the Japanese Ministry of Health, Labor and Welfare for IZERVAY, making it the first approved treatment for suppressing geographic atrophy growth in age-related macular degeneration in Japan. This approval, achieved through an expedited pathway, is expected to significantly impact the treatment landscape for the estimated 100,000 people in Japan affected by this condition, potentially reducing the progression of visual impairment and enhancing patient access to innovative therapies.

The most recent analyst rating on (JP:4503) stock is a Hold with a Yen1900.00 price target. To see the full list of analyst forecasts on Astellas Pharma stock, see the JP:4503 Stock Forecast page.

Pfizer and Astellas Announce Breakthrough in Bladder Cancer Treatment

Pfizer and Astellas Pharma have announced positive results from their Phase 3 EV-303 clinical trial, which evaluated the combination of PADCEV and KEYTRUDA for patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy. The trial demonstrated significant improvements in survival rates, marking a potential new standard of care for this patient population and addressing a critical unmet need.

The most recent analyst rating on (JP:4503) stock is a Hold with a Yen1750.00 price target. To see the full list of analyst forecasts on Astellas Pharma stock, see the JP:4503 Stock Forecast page.